Aurinia Pharmaceuticals Inc (AUPH) vs Recursion Pharmaceuticals, Inc. (RXRX)
- Aurinia Pharmaceuticals Inc AUPH 16.51 −1.32%
- Recursion Pharmaceuticals, Inc. RXRX 3.47 −16.59%
Aurinia Pharmaceuticals Inc and Recursion Pharmaceuticals, Inc. are both Biotechnology companies. Aurinia Pharmaceuticals Inc and Recursion Pharmaceuticals, Inc. are of similar size ($2.2B and $2.2B). Recursion Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Aurinia Pharmaceuticals Inc trades at 6.9×. Aurinia Pharmaceuticals Inc grew revenue faster over the last twelve months: 19.8% against −15.1%. Aurinia Pharmaceuticals Inc has the higher net margin (100.8% vs −945.9%) and the higher return on invested capital (40.8% vs −92.2%). Across the 18 metrics below, Aurinia Pharmaceuticals Inc leads on 15 and Recursion Pharmaceuticals, Inc. on 3.
Valuation
Profitability
| Metric | AUPH | RXRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 90.36% | 3.48% | 65.16% |
| Operating margin | 45.15% | (991.72%) | 0.00% |
| Net margin | 100.84% | (945.92%) | 0.00% |
| Free cash flow margin | 56.20% | (645.82%) | 0.00% |
| Return on equity | 66.12% | (56.58%) | (56.36%) |
| Return on assets | 48.52% | (41.26%) | (48.04%) |
| Return on invested capital | 40.76% | (92.22%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack